应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
PFS Provident Financial Services Inc
休市中 05-01 16:00:00 EDT
22.38
-0.30
-1.32%
盘后
22.38
+0.00
0.00%
16:42 EDT
最高
22.71
最低
22.28
成交量
132.99万
今开
22.66
昨收
22.68
日振幅
1.88%
总市值
29.23亿
流通市值
28.23亿
总股本
1.31亿
成交额
2,989万
换手率
1.05%
流通股本
1.26亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
财报前瞻｜Provident Financial Services Inc本季度营收预计同比增14.74%，机构观点偏谨慎
财报Agent · 04-23
财报前瞻｜Provident Financial Services Inc本季度营收预计同比增14.74%，机构观点偏谨慎
来凯医药-B(02105)：LAE 002(Afuresertib)III期临床试验(AFFIRM-205)达到无进展生存期(PFS)的主要终点
智通财经 · 04-15
来凯医药-B(02105)：LAE 002(Afuresertib)III期临床试验(AFFIRM-205)达到无进展生存期(PFS)的主要终点
达唯珂折戟，创新药研发安全红线再敲警钟
21世纪经济报道 · 03-10
达唯珂折戟，创新药研发安全红线再敲警钟
国产双抗“出海”：FDA已受理依沃西首个海外适应证
每日经济新闻 · 01-30
国产双抗“出海”：FDA已受理依沃西首个海外适应证
异动解读 | 财报利好，Provident Financial Services盘后大涨9.6%
异动解读 · 01-28
异动解读 | 财报利好，Provident Financial Services盘后大涨9.6%
Provident Financial Services, Inc. 公布第四季度及全年业绩并确定年度股东大会日期
美股速递 · 01-28
Provident Financial Services, Inc. 公布第四季度及全年业绩并确定年度股东大会日期
德曲妥珠单抗胃癌新适应证获批，填补临床治疗空白
上观新闻 · 01-22
德曲妥珠单抗胃癌新适应证获批，填补临床治疗空白
优赫得®在华获批治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者
美通社 · 01-22
优赫得®在华获批治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者
财报前瞻 ｜Provident Financial Services Inc本季度营收预计小幅增长，机构观点偏中性
财报Agent · 01-20
财报前瞻 ｜Provident Financial Services Inc本季度营收预计小幅增长，机构观点偏中性
普罗维登特银行年度经济展望调查：企业主从2025年被动乐观转向2026年主动投资
美股速递 · 01-06
普罗维登特银行年度经济展望调查：企业主从2025年被动乐观转向2026年主动投资
美国FDA批准Enhertu联合疗法用于一线HER2阳性乳腺癌治疗
环球市场播报 · 2025-12-16
美国FDA批准Enhertu联合疗法用于一线HER2阳性乳腺癌治疗
吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25
Minhua笔记 · 2025-12-08
吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25
国产双抗疗效击败全球药王 临床研究结果数据已在《柳叶刀》发表了
第一财经 · 2025-03-07
国产双抗疗效击败全球药王 临床研究结果数据已在《柳叶刀》发表了
抵御关税和贸易战风暴，这11只高股息股票或是避风港
老虎资讯综合 · 2025-02-14
抵御关税和贸易战风暴，这11只高股息股票或是避风港
抗关税股息股大揭秘：11只收益稳健的“避风港”！
金十数据 · 2025-02-13
抗关税股息股大揭秘：11只收益稳健的“避风港”！
患者OS和PFS翻倍 辉瑞(PFE.US)联合公布Padcev与Keytruda组合疗法结果
智通财经 · 2025-02-12
患者OS和PFS翻倍 辉瑞(PFE.US)联合公布Padcev与Keytruda组合疗法结果
公积金金融服务盘中异动 快速下挫5.11%报18.21美元
市场透视 · 2025-01-30
公积金金融服务盘中异动 快速下挫5.11%报18.21美元
Provident Finl Servs(PFS.US)：2024年Q4财报实现营收1.817亿美元，前值为9578.8万美元，预期值为2.104亿美元；每股收益为0.37美元，前值为0.36美元，预期值为0.50美元。
金融界 · 2025-01-29
Provident Finl Servs(PFS.US)：2024年Q4财报实现营收1.817亿美元，前值为9578.8万美元，预期值为2.104亿美元；每股收益为0.37美元，前值为0.36美元，预期值为0.50美元。
Provident Finl Servs 2024年第四季度GAAP每股收益$0.37，低于预期的$0.47，销售额$1.8174亿，低于预期的$1.8478亿
财报速递 · 2025-01-29
Provident Finl Servs 2024年第四季度GAAP每股收益$0.37，低于预期的$0.47，销售额$1.8174亿，低于预期的$1.8478亿
【华东医药：独家市场推广产品塞纳帕利胶囊获批上市】华东医药公告，公司全资子公司杭州中美华东制药有限公司独家市场推广产品塞纳帕利胶囊（商品名：派舒宁 ，研发代号：IMP4297）获得国家药品监督管理局批准上市，用于晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在一线含铂化疗达到完全缓解或部分缓解后的维持治疗。塞纳帕利胶囊的获批是基于FLAMES研究，该研究结果显示，塞纳帕利维持治疗能够显著延长晚期卵巢癌患者的无进展生存期（PFS），且不论患者的BRCA基因表达如何，均能从塞纳帕利治疗中获益。同时，塞纳帕利耐受性良好，安全性可控。
金融界 · 2025-01-20
【华东医药：独家市场推广产品塞纳帕利胶囊获批上市】华东医药公告，公司全资子公司杭州中美华东制药有限公司独家市场推广产品塞纳帕利胶囊（商品名：派舒宁 ，研发代号：IMP4297）获得国家药品监督管理局批准上市，用于晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在一线含铂化疗达到完全缓解或部分缓解后的维持治疗。塞纳帕利胶囊的获批是基于FLAMES研究，该研究结果显示，塞纳帕利维持治疗能够显著延长晚期卵巢癌患者的无进展生存期（PFS），且不论患者的BRCA基因表达如何，均能从塞纳帕利治疗中获益。同时，塞纳帕利耐受性良好，安全性可控。
加载更多
公司概况
公司名称：
Provident Financial Services Inc
所属市场：
NYSE
上市日期：
--
主营业务：
Provident Financial Services, Inc.是一家特拉华州公司，于2003年1月15日成为Provident Bank的控股公司。该公司通过其子公司银行开展业务，该银行是一家面向社区和客户的银行，目前在新泽西州北部和中部以及宾夕法尼亚州的雄鹿县、利哈伊县和北安普敦县以及纽约州的拿骚县和皇后区经营全方位服务的分行和贷款生产办事处。该银行还通过其全资子公司Beacon Trust Company提供信托和财富管理服务，并通过其全资子公司Provident Protection Plus, Inc.提供保险服务。
发行价格：
--
{"stockData":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident Financial Services Inc","latestPrice":22.38,"timestamp":1777665600000,"preClose":22.68,"halted":0,"volume":1329920,"hourTrading":{"tag":"盘后","latestPrice":22.38,"preClose":22.38,"latestTime":"16:42 EDT","volume":28964,"amount":648215.52,"timestamp":1777668136865,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01322751322751326,"floatShares":126131374,"shares":130622384,"eps":2.229999,"marketStatus":"休市中","change":-0.3,"latestTime":"05-01 16:00:00 EDT","open":22.66,"high":22.7075,"low":22.28,"amount":29894617.359360002,"amplitude":0.018849,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229999,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777881600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":22.68,"dividendRate":0.042895,"postHourTrading":{"tag":"盘后","latestPrice":22.38,"preClose":22.38,"latestTime":"16:42 EDT","volume":28964,"amount":648215.52,"timestamp":1777668136865,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.145763,"impliedVol":0.3668,"impliedVolPercentile":0.6972},"requestUrl":"/m/hq/s/PFS","defaultTab":"news","newsList":[{"id":"1142590005","title":"财报前瞻｜Provident Financial Services Inc本季度营收预计同比增14.74%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1142590005","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142590005?lang=zh_cn&edition=full","pubTime":"2026-04-23 02:37","pubTimestamp":1776883022,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc将于2026年04月29日发布财报，市场预计营收和盈利保持同比增长，净息差与拨备仍是关键变量。市场一致预期本季度Provident Financial Services Inc营收为2.08亿美元，同比增长14.74%；EBIT为1.07亿美元，同比增长13.58%；调整后每股收益为0.55美元，同比增长16.95%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Provident Financial Services Inc本季度营收预计同比增14.74%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473918","title":"来凯医药-B(02105)：LAE 002(Afuresertib)III期临床试验(AFFIRM-205)达到无进展生存期(PFS)的主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473918","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627473918?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:22","pubTimestamp":1776212528,"startTime":"0","endTime":"0","summary":"II期临床试验是一项多中心、随机、双盲、安慰剂对照的关键性研究，旨在评估该联合疗法的抗肿瘤疗效及安全性。.每日一次口服LAE 002的治疗，患者耐受性良好，因不良事件而中止治疗的比例极低。本集团有权就许可区域内LAE 002的未来净销售额收取梯度销售分成，分成比率在十余个百分点至二十余个百分点。本集团计划在中国以外地区寻求战略合作伙伴，以加速LAE 002在国际市场的开发及商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","02105","BK4195","BK4134","BK1161","BK4211","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618987798","title":"达唯珂折戟，创新药研发安全红线再敲警钟","url":"https://stock-news.laohu8.com/highlight/detail?id=2618987798","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618987798?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:14","pubTimestamp":1773105251,"startTime":"0","endTime":"0","summary":"达唯珂由法国药企益普生旗下Epizyme开发，为全球同类首创的EZH2甲基转移酶抑制剂。达唯珂是全球首个且唯一获批用于滤泡性淋巴瘤的口服EZH2抑制剂。此次产品撤市、相关临床试验全面终止后，该细分领域精准治疗方案的空白将再次凸显，临床未满足需求亟待新一代创新药填补。2025年4月，公司以6.085亿美元现金出售上海和黄药业45%股权，仅保留5%股权，全面聚焦创新药研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310091707a45cda1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310091707a45cda1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2637428348.USD","LU0963586101.USD","BK4548","LU0545562505.USD","BK4081","LU1880398554.USD","IE00B19Z4B17.USD","HCM","BK4195","BK4226","CRS","LU2449327464.USD","IE00BMG7P926.USD","IE0009354923.USD","IE00BMG7P819.SGD","LU1228905540.USD","IE00BZ18W456.USD","IE0031619046.USD","BK4585","LU1803068623.USD","IE00B29SXL02.USD","BK4588","BK4531","BR","BK4007","LU0390134368.USD","IE0034235188.USD","PFS","LU1228905037.USD","LU2065731478.USD","IE00B66KJ199.SGD","BK4106","BK4211","IE00B7SZL793.SGD","ORR","IE00BZ18W340.USD","BK4187","IE00BMG7P694.USD","BK4006","LU1883839398.USD","IE00B29SXK94.USD","IE00BMQBXF63.USD","IE00BMG7P587.USD","ES","LU1880398471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607061264","title":"国产双抗“出海”：FDA已受理依沃西首个海外适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2607061264","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607061264?lang=zh_cn&edition=full","pubTime":"2026-01-30 10:47","pubTimestamp":1769741258,"startTime":"0","endTime":"0","summary":"1月30日，康方生物在官方公众号上宣布，美国食品药品监督管理局（FDA）已受理PD-1/VEGF双抗依沃西联合化疗治疗第三代EGFR-TKI治疗进展的EGFR突变的非鳞状非小细胞肺癌（NSCLC）的生物制品许可申请（BLA）。FDA给出的PDUFA（处方药用户付费法案）日期为2026年11月14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303636681397.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303636681397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4097","PFS","OS","BK4195","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166238844","title":"异动解读 | 财报利好，Provident Financial Services盘后大涨9.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166238844","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166238844?lang=zh_cn&edition=full","pubTime":"2026-01-28 06:43","pubTimestamp":1769553802,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc (PFS) 今日盘后股价大幅上涨9.60%，引发了市场广泛关注。消息面上，公司于盘后时段正式发布了其第四季度及整个财年的财务业绩报告，并确定了年度股东大会的日期。财报的发布是影响股价的关键事件，此次盘后大涨通常表明其公布的业绩数据可能超出了市场预期，为投资者带来了积极信号。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133317496","title":"Provident Financial Services, Inc. 公布第四季度及全年业绩并确定年度股东大会日期","url":"https://stock-news.laohu8.com/highlight/detail?id=1133317496","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133317496?lang=zh_cn&edition=full","pubTime":"2026-01-28 06:16","pubTimestamp":1769552177,"startTime":"0","endTime":"0","summary":"Provident Financial Services, Inc. 已正式发布其第四季度财务报告以及整个财年的最终收益数据。与此同时，公司也确定了即将召开的年度股东大会的具体日期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","PFS","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605989254","title":"德曲妥珠单抗胃癌新适应证获批，填补临床治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2605989254","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605989254?lang=zh_cn&edition=full","pubTime":"2026-01-22 19:18","pubTimestamp":1769080687,"startTime":"0","endTime":"0","summary":"由阿斯利康和第一三共共同开发与商业化的优赫得（英文商品名：Enhertu，通用名：注射用德曲妥珠单抗）今天获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627553572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["OS","BK4097","ADC","BK4211","BK4231","BK4195","ORR","PFS","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605495703","title":"优赫得®在华获批治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495703","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605495703?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:38","pubTimestamp":1769078280,"startTime":"0","endTime":"0","summary":"研究显示，对于局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者，与雷莫西尤单抗+紫杉醇相比，德曲妥珠单抗带来具有显著统计学差异和临床意义的总生存期改善。自一年多前首次在中国获批用于HER2阳性局部晚期或转移性胃癌以来，德曲妥珠单抗仅可用于三线及后线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4868984_ZH68984_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2462157665.USD","IE00BFMHRM44.USD","LU0792757196.USD","BK4231","LU0320765992.SGD","LU1880398471.USD","SG9999001440.SGD","OS","BK4585","IE000M9KFDE8.USD","BK4527","LU1046421795.USD","LU0868494617.USD","LU2417539215.USD","CSCO","BK4579","BK4588","LU1221951129.SGD","LU1894683348.USD","LU1571399168.USD","LU2506952097.USD","ADC","LU1196500208.SGD","LU1221951046.USD","ORR","LU1066053197.SGD","AZN","LU1066051498.USD","SG9999015978.USD","BK4195","LU0109394709.USD","PFS","LU2506951875.HKD","LU1880398554.USD","IE00BKVL7J92.USD","BK4612","LU2237443895.HKD","BK4560","BK4097","BK4080","LU0234572021.USD","LU1244550494.USD","LU1929549753.HKD","LU2237443549.SGD","LU2237443622.USD","LU2237443382.USD","LU2247934214.USD","SG9999015945.SGD","LU1244550577.SGD","LU2506951958.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106932996","title":"财报前瞻 ｜Provident Financial Services Inc本季度营收预计小幅增长，机构观点偏中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1106932996","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106932996?lang=zh_cn&edition=full","pubTime":"2026-01-20 10:54","pubTimestamp":1768877699,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc将于2026年01月27日发布最新季度财报，市场关注核心盈利修复与资产质量趋势对估值的影响。市场一致预期显示，Provident Financial Services Inc本季度营收预计为2.08亿美元，同比增长12.34%；调整后每股收益预计为0.56美元，同比增长10.76%；EBIT预计为1.11亿美元，同比增长10.79%。上季度Provident Financial Services Inc实现营收1.94亿美元，毛利率数据未披露；归属母公司净利润为7,172.00万美元，净利率为33.40%；调整后每股收益0.55美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 ｜Provident Financial Services Inc本季度营收预计小幅增长，机构观点偏中性","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102063075","title":"普罗维登特银行年度经济展望调查：企业主从2025年被动乐观转向2026年主动投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1102063075","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102063075?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:08","pubTimestamp":1767704939,"startTime":"0","endTime":"0","summary":"根据普罗维登特银行发布的年度经济展望调查，美国企业主对未来的心态预计将发生显著转变。调查结果显示，2025年企业界普遍持谨慎乐观态度，更多表现为观望和被动期待；而进入2026年，这种情绪将逐步转化为实际行动，企业主计划扩大资本支出、加大技术创新投入，并积极拓展新市场。普罗维登特银行首席经济学家分析称，这种从\"被动乐观\"到\"主动投资\"的演变，可能成为推动2026年经济加速的关键催化剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","PFS","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591359889","title":"美国FDA批准Enhertu联合疗法用于一线HER2阳性乳腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2591359889","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591359889?lang=zh_cn&edition=full","pubTime":"2025-12-16 23:45","pubTimestamp":1765899900,"startTime":"0","endTime":"0","summary":"FDA批准阿斯利康（AZN）与第一三共（Daiichi Sankyo，TYO：4568）的fam-trastuzumab deruxtecan（Enhertu）联合帕妥珠单抗（pertuzumab）用于一线治疗，因DESTINY-Breast09试验显示其中位无进展生存期（PFS）达40.7个月，优于标准THP方案的26.9个月；帕妥珠单抗由罗氏（SWX：ROG）销售。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-16/doc-inhaziff7927164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","LU0109394709.USD","LU2236285917.USD","LU2462157665.USD","PFS","BK4007","BK4211","AZN","LU0889565916.HKD","LU2417539215.USD","BK4588","LU2456880835.USD","BK4195","LU0320765992.SGD","LU1829250122.USD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590451393","title":"吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451393","media":"Minhua笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590451393?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:58","pubTimestamp":1765166299,"startTime":"0","endTime":"0","summary":"在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。III期iMMagine-3试验正在招募中，该研究将Anito-cel与标准治疗比较，预计2026年获得数据；该药物获FDA快速通道、孤儿药和RMAT资格。ICANS 发生率为 8%，其中 1 例为 3 级；其余均为 2 级或更低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","PFS","LU1066051498.USD","BK4109","LU0320765992.SGD","LU0882574055.USD","IE00BKVL7J92.USD","LU1778281490.HKD","SG9999015952.SGD","LU0889565916.HKD","LU0234570918.USD","SG9999015945.SGD","GILD","IE0002270589.USD","BK4550","LU0289739699.SGD","IE00B7SZLL34.SGD","LU1839511570.USD","IE00B7SZL793.SGD","LU0823416689.USD","IE00B19Z3B42.SGD","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4578","BK4195","LU1674673428.USD","SG9999015986.USD","BK4588","LU1674673691.USD","BK4097","BK4568","BK4139","ASH","KOL","SG9999015978.USD","BK4187","LU1585245621.USD","ORR","OS","BK4566","BK4532","CR","CRS","LU1571399168.USD","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","LU1430594728.SGD","IE00B3T34201.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517910639","title":"国产双抗疗效击败全球药王 临床研究结果数据已在《柳叶刀》发表了","url":"https://stock-news.laohu8.com/highlight/detail?id=2517910639","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517910639?lang=zh_cn&edition=full","pubTime":"2025-03-07 17:00","pubTimestamp":1741338046,"startTime":"0","endTime":"0","summary":"【国产双抗疗效击败全球药王 临床研究结果数据已在《柳叶刀》发表了】去年9月8日，国产企业康方生物（09926.HK）双抗药物依沃西，从疗效上战胜了全球药王帕博利珠单抗（即“K药”）的消息传开后，引发资本市场沸腾。时至今日，康方生物港股股价涨幅在50%左右。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503073339808148.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503073339808148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999002224.SGD","SG9999001176.SGD","IE00BJT1NW94.SGD","BK4550","LU1061106388.HKD","LU0965509010.AUD","LU1699723380.USD","IE00B1BXHZ80.USD","LU0106261372.USD","LU1023059063.AUD","PFS","LU1057294990.SGD","LU1989772840.SGD","LU0203345920.USD","LU0211331839.USD","BK4534","BK4007","SG9999014575.USD","LU0238689110.USD","SGXZ57979304.SGD","LU1093756325.SGD","LU2324357040.USD","LU0208291251.USD","LU1941712264.USD","MRK","IE00BJJMRZ35.SGD","LU1720050803.USD","LU0320765489.SGD","LU1066051498.USD","BK1161","IE00BBT3K403.USD","LU0985320562.USD","LU1066053197.SGD","LU2361044865.SGD","IE000M9KFDE8.USD","LU1794554557.SGD","LU2361044949.HKD","LU0265550359.USD","SG9999002232.USD","09926","IE00BLSP4239.USD","LU0320765646.SGD","BK4585","LU0070302665.USD","LU1116320737.USD","LU0348784397.USD","LU2089984988.USD","LU0265550946.USD","LU1989771016.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197399939","title":"抵御关税和贸易战风暴，这11只高股息股票或是避风港","url":"https://stock-news.laohu8.com/highlight/detail?id=1197399939","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197399939?lang=zh_cn&edition=full","pubTime":"2025-02-14 13:08","pubTimestamp":1739509687,"startTime":"0","endTime":"0","summary":"关税和贸易战——以及关于关税和贸易战的传闻——将长期存在。股息投资者通常追求稳定性，而美国总统特朗普的贸易政策却截然相反。不过，许多深受投资者喜爱的高股息股票确实存在关税风险。在这一行业框架下，我们可以寻找一些免受关税影响的高股息股票。出人意料的是，其较低的关税风险正是由于其在美国业务和制造规模有限。该公司在2月6日公布了好于预期的盈利和指引后，其股价跃升了11%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/a89ab3e0896a7b709dd40313a2698f0d","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/a89ab3e0896a7b709dd40313a2698f0d"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6c099c6dea4ae5c338322ee06c371426","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"抵御关税和贸易战风暴，这11只高股息股票或是避风港","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DTE","STWD","AES","WTRG","NWE","CVS","PFS","EVRG","NLY","VNOM"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2511155595","title":"抗关税股息股大揭秘：11只收益稳健的“避风港”！","url":"https://stock-news.laohu8.com/highlight/detail?id=2511155595","media":"金十数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511155595?lang=zh_cn&edition=full","pubTime":"2025-02-13 16:30","pubTimestamp":1739435407,"startTime":"0","endTime":"0","summary":"面对不断变化的关税和贸易战，股息投资者该如何守住收益？这11只股票不仅能应对关税冲击，还能提供高达7.4%的超高股息回报。","market":"hk","thumbnail":"https://img.jin10.com/news/24/12/8M4TV7H7wY_2HySswSjdT.png/lite","type":0,"news_type":0,"thumbnails":["https://img.jin10.com/news/24/12/8M4TV7H7wY_2HySswSjdT.png/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=163059&type=news&data_type=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"xnew_highlight","symbols":["LU0949170772.SGD","BK4110","LU0162691827.USD","LU0545562505.USD","LU0211331839.USD","LU1228905037.USD","LU0106831901.USD","LU1366192091.USD","LU0314106906.USD","LU2125154935.USD","LU2462157665.USD","BK4555","NLY","VNOM","LU0690374615.EUR","LU1043141396.HKD","LU0320765489.SGD","LU0738911758.USD","LU0072461881.USD","PM","BK4213","BK4207","BK4588","LU0061475181.USD","LU0426412945.USD","LU0980610538.SGD","LU1228905540.USD","BK4504","LU2456880835.USD","IE00BSNM7G36.USD","PFS","LU0130102774.USD","LU0052756011.USD","LU1121112475.USD","F","BK4195","GB00B4QBRK32.GBP","BK4211","LU1066051811.HKD","LU2125154778.USD","LU1267930227.SGD","REIT","LU0661504455.SGD","CVS","LU1699723380.USD","LU2417539215.USD","LU0170899867.USD","LU0128525689.USD","SG9999003800.SGD","LU0648001328.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2510631737","title":"患者OS和PFS翻倍 辉瑞(PFE.US)联合公布Padcev与Keytruda组合疗法结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2510631737","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510631737?lang=zh_cn&edition=full","pubTime":"2025-02-12 14:15","pubTimestamp":1739340941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，辉瑞与安斯泰来公司日前宣布，将在美国临床肿瘤学会泌尿生殖系统癌症研讨会上，公布3期临床试验EV-302的长期随访结果。这项研究评估了抗体偶联药物Padcev与Keytruda联用，治疗既往未接受治疗的局部晚期或转移性尿路上皮癌患者的效果。结果显示，与化疗相比，Padcev加Keytruda可将患者死亡风险降低49%。联合治疗组的中位PFS为12.5个月，而化疗组为6.3个月。安全性特征与以往结果一致，未发现新的安全问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1248781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0965509010.AUD","SG9999001176.USD","IE00B2B36J28.USD","BK4534","LU1883839398.USD","LU0861579265.USD","IE00BBT3K403.USD","LU2089984988.USD","BK4559","BK4516","IE0009355771.USD","SG9999001440.SGD","BK4211","LU0238689110.USD","LU1941712264.USD","LU0070302665.USD","LU2361045086.USD","LU0965508806.USD","LU1116320737.USD","LU0106261372.USD","LU1037948897.HKD","LU1894683348.USD","SG9999013999.USD","PFE","LU1061106388.HKD","LU1989772840.SGD","LU1934455863.HKD","IE00BFTCPJ56.SGD","PFS","LU2361044865.SGD","SG9999003800.SGD","LU2361044949.HKD","BK4581","SG9999015358.SGD","LU0265550946.USD","LU0203347892.USD","MRK","BK4550","SG9999015341.SGD","BK4568","LU0306806265.USD","LU0985320562.USD","LU0289739699.SGD","LU1116320901.HKD","LU1989772923.USD","LU0170899867.USD","IE00BLSP4239.USD","LU0321505868.SGD","LU1585245621.USD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507658176","title":"公积金金融服务盘中异动 快速下挫5.11%报18.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507658176","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507658176?lang=zh_cn&edition=full","pubTime":"2025-01-30 00:07","pubTimestamp":1738166856,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日00时07分，公积金金融服务股票出现异动，股价大幅下跌5.11%。截至发稿，该股报18.21美元/股，成交量35.6896万股，换手率0.27%，振幅2.92%。公积金金融服务股票所在的银行行业中，整体涨幅为0.40%。其相关个股中，格伦伯尼万通金控、Chemung Financial Corp、Merchants Bancorp涨幅较大，Lendingclub Corporation、Eastside Distilling, Inc.、UMB金融较为活跃，换手率分别为5.04%、1.44%、1.18%，振幅较大的相关个股有Eastside Distilling, Inc.、格伦伯尼万通金控、爱国者国家合众银行，振幅分别为23.37%、19.48%、13.31%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130000736abbc6ca8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130000736abbc6ca8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4195","BK4211","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507249365","title":"Provident Finl Servs(PFS.US)：2024年Q4财报实现营收1.817亿美元，前值为9578.8万美元，预期值为2.104亿美元；每股收益为0.37美元，前值为0.36美元，预期值为0.50美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507249365","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507249365?lang=zh_cn&edition=full","pubTime":"2025-01-29 06:11","pubTimestamp":1738102317,"startTime":"0","endTime":"0","summary":"Provident Finl Servs(PFS.US)：2024年Q4财报实现营收1.817亿美元，前值为9578.8万美元，预期值为2.104亿美元；每股收益为0.37美元，前值为0.36美元，预期值为0.50美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/29061147883814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188952262","title":"Provident Finl Servs 2024年第四季度GAAP每股收益$0.37，低于预期的$0.47，销售额$1.8174亿，低于预期的$1.8478亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1188952262","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188952262?lang=zh_cn&edition=full","pubTime":"2025-01-29 06:06","pubTimestamp":1738101973,"startTime":"0","endTime":"0","summary":"Provident Finl Servs报告其季度每股收益为$0.37，低于分析师普遍预期的$0.47，差距为21.28%。与去年同期的每股收益$0.36相比，这一数据增长了2.78%。以上内容来自Benzinga Earnings专栏，原文如下：Provident Finl Servs reported quarterly earnings of $0.37 per share which missed the analyst consensus estimate of $0.47 by 21.28 percent. This is a 2.78 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $181.74 million which missed the analyst consensus estimate of $184.78 million by 1.65 percent. T","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Provident Finl Servs 2024年第四季度GAAP每股收益$0.37，低于预期的$0.47，销售额$1.8174亿，低于预期的$1.8478亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504005470","title":"【华东医药：独家市场推广产品塞纳帕利胶囊获批上市】华东医药公告，公司全资子公司杭州中美华东制药有限公司独家市场推广产品塞纳帕利胶囊（商品名：派舒宁 ，研发代号：IMP4297）获得国家药品监督管理局批准上市，用于晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在一线含铂化疗达到完全缓解或部分缓解后的维持治疗。塞纳帕利胶囊的获批是基于FLAMES研究，该研究结果显示，塞纳帕利维持治疗能够显著延长晚期卵巢癌患者的无进展生存期（PFS），且不论患者的BRCA基因表达如何，均能从塞纳帕利治疗中获益。同时，塞纳帕利耐受性良好，安全性可控。","url":"https://stock-news.laohu8.com/highlight/detail?id=2504005470","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504005470?lang=zh_cn&edition=full","pubTime":"2025-01-20 18:31","pubTimestamp":1737369099,"startTime":"0","endTime":"0","summary":"华东医药公告，公司全资子公司杭州中美华东制药有限公司独家市场推广产品塞纳帕利胶囊（商品名：派舒宁 ，研发代号：IMP4297）获得国家药品监督管理局批准上市，用于晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在一线含铂化疗达到完全缓解或部分缓解后的维持治疗。塞纳帕利胶囊的获批是基于FLAMES研究，该研究结果显示，塞纳帕利维持治疗能够显著延长晚期卵巢癌患者的无进展生存期（PFS），且不论患者的BRCA基因表达如何，均能从塞纳帕利治疗中获益。同时，塞纳帕利耐受性良好，安全性可控。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/20183147617222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4211","BK0196","BK0209","BK1574","BK0175","01477","000963","PFS","BK4195","BK0187","BK0132","LU1969619763.USD","BK1191","BK0188","LU2328871848.SGD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.provident.bank","stockEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":0.0517},{"period":"3month","weight":0.0108},{"period":"6month","weight":0.2236},{"period":"1year","weight":0.3409},{"period":"ytd","weight":0.1332}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Provident Financial Services, Inc.是一家特拉华州公司，于2003年1月15日成为Provident Bank的控股公司。该公司通过其子公司银行开展业务，该银行是一家面向社区和客户的银行，目前在新泽西州北部和中部以及宾夕法尼亚州的雄鹿县、利哈伊县和北安普敦县以及纽约州的拿骚县和皇后区经营全方位服务的分行和贷款生产办事处。该银行还通过其全资子公司Beacon Trust Company提供信托和财富管理服务，并通过其全资子公司Provident Protection Plus, Inc.提供保险服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.304348,"avgChangeRate":-0.021667},{"month":2,"riseRate":0.375,"avgChangeRate":-0.016026},{"month":3,"riseRate":0.458333,"avgChangeRate":-0.003293},{"month":4,"riseRate":0.5,"avgChangeRate":0.008655},{"month":5,"riseRate":0.458333,"avgChangeRate":-0.011633},{"month":6,"riseRate":0.478261,"avgChangeRate":-0.000381},{"month":7,"riseRate":0.652174,"avgChangeRate":0.040433},{"month":8,"riseRate":0.521739,"avgChangeRate":-0.005847},{"month":9,"riseRate":0.347826,"avgChangeRate":-0.017472},{"month":10,"riseRate":0.652174,"avgChangeRate":0.032054},{"month":11,"riseRate":0.695652,"avgChangeRate":0.033616},{"month":12,"riseRate":0.565217,"avgChangeRate":0.013167}],"exchange":"NYSE","name":"Provident Financial Services Inc","nameEN":"Provident"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Provident Financial Services Inc,PFS,Provident Financial Services Inc股票,Provident Financial Services Inc股票老虎,Provident Financial Services Inc股票老虎国际,Provident Financial Services Inc行情,Provident Financial Services Inc股票行情,Provident Financial Services Inc股价,Provident Financial Services Inc股市,Provident Financial Services Inc股票价格,Provident Financial Services Inc股票交易,Provident Financial Services Inc股票购买,Provident Financial Services Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}